Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Leases (2019 - 2025)

Eton Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $460000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases rose 329.91% to $460000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $460000.0, a 329.91% increase, with the full-year FY2025 number at $460000.0, up 329.91% from a year prior.
  • Operating Leases hit $460000.0 in Q4 2025 for Eton Pharmaceuticals, down from $480000.0 in the prior quarter.
  • Over the last five years, Operating Leases for ETON hit a ceiling of $492000.0 in Q2 2025 and a floor of $15000.0 in Q4 2021.
  • Historically, Operating Leases has averaged $135947.4 across 5 years, with a median of $79000.0 in 2021.
  • Biggest five-year swings in Operating Leases: crashed 84.85% in 2021 and later soared 613.33% in 2022.
  • Tracing ETON's Operating Leases over 5 years: stood at $15000.0 in 2021, then soared by 613.33% to $107000.0 in 2022, then tumbled by 79.44% to $22000.0 in 2023, then skyrocketed by 386.36% to $107000.0 in 2024, then soared by 329.91% to $460000.0 in 2025.
  • Business Quant data shows Operating Leases for ETON at $460000.0 in Q4 2025, $480000.0 in Q3 2025, and $492000.0 in Q2 2025.